![Amylyx Pharmaceuticals Inc](/common/images/company/N_AMLX.png)
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, July 18, 2024 NEW YORK, July 18, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (โAmylyxโ or the โCompanyโ) today announced that Amylyxโ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.32 | -13.7931034483 | 2.32 | 2.42 | 2 | 2165910 | 2.17247192 | CS |
4 | 0.36 | 21.9512195122 | 1.64 | 2.42 | 1.62 | 2694029 | 1.98990653 | CS |
12 | 0.21 | 11.7318435754 | 1.79 | 2.42 | 1.575 | 1838200 | 1.88978779 | CS |
26 | -13.01 | -86.6755496336 | 15.01 | 19.9488 | 1.575 | 2518817 | 4.58356822 | CS |
52 | -20.53 | -91.1229471815 | 22.53 | 25.48 | 1.575 | 1948745 | 9.1130388 | CS |
156 | -19 | -90.4761904762 | 21 | 41.9297 | 1.575 | 1361445 | 16.51406968 | CS |
260 | -19 | -90.4761904762 | 21 | 41.9297 | 1.575 | 1361445 | 16.51406968 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.